Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The importance of doing trials right while doing the right trials.

Literature DB >> 22072734

The importance of doing trials right while doing the right trials.

Abstract

Effort is being expended in investigating efficiency measures (i.e., doing trials right) through achievement of accrual and endpoint goals for clinical trials. It is time to assess the impact of such trials on meeting the critical needs of cancer patients by establishing effectiveness measures (i.e., doing the right trials).

Entities: Disease Species

Mesh：

Year: 2011 PMID： 22072734 PMCID： PMC4494860 DOI： 10.1158/1078-0432.CCR-11-2586

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

7 in total

1. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program.

Authors: John F Scoggins; Scott D Ramsey
Journal: J Natl Cancer Inst Date: 2010-08-03 Impact factor: 13.506

2. Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice.

Authors: Vincent C Tam; Ian F Tannock; Christine Massey; Jennifer Rauw; Monika K Krzyzanowska
Journal: J Clin Oncol Date: 2011-07-11 Impact factor: 44.544

3. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.

Authors: Anneke T Schroen; Gina R Petroni; Hongkun Wang; Monika J Thielen; Robert Gray; Jacqueline Benedetti; Xiaofei F Wang; Daniel J Sargent; Donald L Wickerham; Walter Cronin; Benjamin Djulbegovic; Craig L Slingluff
Journal: Clin Cancer Res Date: 2011-10-05 Impact factor: 12.531

4. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.

Authors: David M Dilts; Alan B Sandler
Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544

5. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.

Authors: Edward L Korn; Boris Freidlin; Margaret Mooney; Jeffrey S Abrams
Journal: J Clin Oncol Date: 2010-11-08 Impact factor: 44.544

6. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.

Authors: Steven K Cheng; Mary S Dietrich; David M Dilts
Journal: Clin Cancer Res Date: 2010-11-09 Impact factor: 12.531

7. Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology.

Authors: Scott Ramsey; John Scoggins
Journal: Oncologist Date: 2008-09-15

7 in total

5 in total

1. Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.

Authors: Caroline S Bennette; Scott D Ramsey; Cara L McDermott; Josh J Carlson; Anirban Basu; David L Veenstra
Journal: J Natl Cancer Inst Date: 2015-12-29 Impact factor: 13.506

2. Accrual Prediction Program: A web-based clinical trials tool for monitoring and predicting accrual for early-phase cancer studies.

Authors: Junhao Liu; Jo A Wick; Dinesh Pal Mudaranthakam; Yu Jiang; Matthew S Mayo; Byron J Gajewski
Journal: Clin Trials Date: 2019-08-26 Impact factor: 2.486